ArticleTransplantation direct2025
Extracorporeal Photopheresis: Does It Have a Potential Place Among Cell-based Therapies?
Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Potential Biomarkers of Therapeutic Response to ECP in Solid Organ Transplantation.Transplantation direct · 2025Article
- exTra Mini-review Series on ECP in Transplantation.Transplantation direct · 2025Article
- Extracorporeal Photopheresis in Lung Transplantation: Present Applications and Emerging Research.Transplantation direct · 2025Article
- Potential Impact of Extracorporeal Photopheresis on Trained Immunity and Organ Transplant Acceptance.Transplantation direct · 2025Article
- Extracorporeal Photopheresis Stimulates Tissue Repair after Transplantation.Transplantation direct · 2025Article
- Extracorporeal Photopheresis: Secreted Factors That Promote Immunomodulation.Transplantation direct · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracorporeal photopheresis (ECP) is a therapeutic intervention for modulating immune responses using an autologous apoptotic cell-based product, known as a photopheresate. The process of generating photopheresates offers attractive possibilities for manipulating distinct leukocyte subsets to either augment or dampen immune responses, depending on the disease context. This review discusses current uses of ECP as a cell-based therapy and introduces possible strategies to enhance the potency of photopheresates. In Europe, ECP is regulated under the European Union Tissue Directive, but innovative applications in solid organ transplantation, including modifications of the procedure, may force its reclassification as an Advanced Therapy Medicinal Product. Such modifications might include loading dendritic cells with antigens, polarizing dendritic cells toward immunogenic or tolerogenic states, or genetically manipulating leukocyte subsets. In conclusion, although ECP is a long-established, safe, and effective therapy, the more rigorous standards applied to Advanced Therapy Medicinal Product manufacture could help to ensure the quality of photopheresates applied to solid organ transplant recipients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.